Stock A049960 CELL BIOTECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Cell Biotech Co., Ltd.

Equities

A049960

KR7049960008

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 02/07/2024 am IST 		5-day change 1st Jan Change
13,400 KRW -0.15% Intraday chart for Cell Biotech Co., Ltd. +6.94% +19.43%
2023 Cell Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2022 Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022. CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cell Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022.
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022.
CI
Cell Biotech Co., Ltd.'s Equity Buyback announced on February 18, 2022, has expired with 227,719 shares, representing 3.24% for KRW 3,718.70 million.
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022.
CI
Cell Biotech Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
CI
Cell Biotech Co., Ltd. authorizes a Buyback Plan.
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
CI
Cell Biotech Co., Ltd.'s Equity Buyback announced on July 31, 2019, has expired with 432,381 shares, representing 5.8% for KRW 7,328 million.
CI
Cell Biotech Acquire a European Patent for Anticancer Protein P8 Originated from Lactobacillus rhamnosus
CI
Cell Biotech Co., Ltd.'s Equity Buyback Plan Extended till July 29, 2021.
CI
Cell Biotech Co., Ltd.(KOSDAQ:A049960) dropped from S&P Global BMI Index
CI
Cell Biotech Co., Ltd.'s Equity Buyback Plan Extended till January 29, 2021.
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
CI
Psomagen and Cell Biotech to Enter into Agreement
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A049960 Stock
  4. News Cell Biotech Co., Ltd.